NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2A Recommendation4,5*
The NCCN Guidelines® for Soft Tissue Sarcoma (STS) recommend olaratumab (LARTRUVO) in combination with doxorubicin for treatment of adult patients with STS.
The NCCN Guidelines for Uterine Neoplasms recommend olaratumab (LARTRUVO) in combination with doxorubicin as a systemic therapy option for the treatment of uterine sarcoma.†
LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
*Category 2A recommendation is based on lower-level evidence and there is uniform NCCN consensus that the intervention is appropriate.
†Clinical trials are strongly recommended.
‡The clinical benefits of LARTRUVO for any one histologic subtype of STS have not been established.
The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.